Hyderabad-headquartered Aurobindo Pharma Ltd has informed that the company has received approvals from the South Africa’s Medicines Control Council (MCC) to manufacture and market nine products in South Africa.

These products, with an estimated generic market size of ZAR 165 million in the local market, include Auro - Lisinopril Co, Auro-Amlodipine, Auro - Finasteride, Zinoxime, Zolid, Yomax, Lazivir, Lisinozide and Profina.

Aurobindo Pharma Limited engages in the research, development, manufactures, and sale of active pharmaceutical ingredients, intermediates, and generic formulations worldwide.

The company now has a total of 31 marketing authorizations, which are approved by MCC.